Biohaven Ltd. BHVN
Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. We are advancing our innovative portfolio of therapeutics, leveraging our proven drug development experience and multiple proprietary drug development platforms.
On October 3, 2022, Biohaven Pharmaceutical Holding Company Ltd. (the "Former Parent") completed the distribution to holders of its common shares of all of our outstanding common shares and the spin-off of Biohaven Ltd. from the Former Parent (the "Separation"). As a result of the Separation, Biohaven became an independent, publicly traded company as of October 3, 2022, and commenced regular way trading under the symbol "BHVN"' on the New York Stock Exchange on October 4, 2022.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| R&D | $635.1M | $795.9M | $373.3M | $437.1M | $181.5M | $98.5M | — |
| SG&A | $110.3M | $89.2M | $62.8M | $130.9M | $37.4M | $16.0M | — |
| Total operating expenses | $745.4M | $885.1M | $436.1M | $567.9M | $218.9M | $114.5M | — |
| Operating income | -$745.4M | -$885.1M | -$436.1M | -$567.9M | -$218.9M | -$114.5M | — |
| Pre-tax income | -$737.4M | -$845.7M | -$409.6M | -$569.8M | -$212.4M | -$118.7M | — |
| Income tax | $1.4M | $735.0K | $1.4M | $438.0K | $1.4M | $0 | — |
| Net income | -$738.8M | -$846.4M | -$408.2M | -$570.3M | -$213.8M | -$118.7M | — |
| EPS, basic | -6.86 | -9.28 | -5.73 | -12.75 | -5.43 | -3.01 | — |
| EPS, diluted | -6.86 | -9.28 | -5.73 | -12.75 | -5.43 | -3.01 | — |
| Shares, diluted (wtd. avg.) | $107.6M | $91.2M | $71.2M | $44.7M | $39.4M | $39.4M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $230.0M | $99.1M | $248.4M | $242.6M | $77.1M | $83.5M | $9.9M |
| Short-term investments | $89.2M | $386.9M | $133.4M | $260.5M | $0 | — | — |
| Total current assets | $368.3M | $538.5M | $442.4M | $587.0M | $94.8M | — | — |
| Property, plant and equipment | $16.0M | $17.3M | $17.2M | $17.5M | $13.0M | — | — |
| Goodwill | $1.4M | $1.4M | $1.4M | $1.4M | $1.4M | — | — |
| Other intangibles | $18.4M | $18.4M | $18.4M | $18.4M | $18.4M | — | — |
| Total assets | $451.4M | $615.1M | $513.2M | $661.8M | $142.1M | — | — |
| Accounts payable | $11.6M | $18.0M | $15.6M | $10.7M | $4.8M | — | — |
| Total current liabilities | $115.9M | $154.2M | $55.4M | $90.0M | $41.9M | — | — |
| Total liabilities | $399.4M | $191.7M | $85.2M | $123.0M | $47.4M | — | — |
| Retained earnings | -$2.08B | -$1.35B | -$499.3M | -$91.1M | $0 | — | — |
| Total equity | $52.1M | $423.4M | $428.0M | $538.8M | $34.7M | $16.8M | $14.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$609.4M | -$582.5M | -$331.7M | -$297.7M | -$145.8M | -$76.0M | — |
| Depreciation and amortisation | $9.9M | $7.9M | $6.9M | $1.4M | $1.4M | $72.0K | — |
| Stock-based compensation | $112.4M | $72.0M | $28.8M | $193.6M | $65.6M | $29.5M | — |
| Capital expenditure | $715.0K | $4.0M | $3.0M | $6.1M | $938.0K | $1.1M | — |
| Investing cash flow | $300.6M | -$245.0M | $129.8M | -$304.8M | $944.0K | -$2.7M | — |
| Financing cash flow | $439.1M | $677.8M | $211.9M | $767.6M | $138.4M | $152.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001935979-26-000020.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |